



Life Without Limitations

OSSUR INVESTOR PRESENTATION

30 OCTOBER 2007



Life Without Limitations

ÖSSUR – Q3 2007

ÖSSUR – Q3 2007

JON SIGURDSSON – PRESIDENT & CEO

ÖSSUR – Q3 2007

HIGHLIGHTS Q3 2007



Life Without Limitations

- Sales USD 82.3 million, up by 31% from Q3 2006
- Organic sales growth 11%
- Pro forma sales growth 11%
- EBITDA USD 14.1 million, up by 16% from Q3 2006
- EBITDA margin 17.1% compared to 19.3% in Q3 2006
- Signs of a turnaround in Bracing & Support sales in Americas
- Exceptional growth in traditional Europe




MARKETS Q3 2007



Life Without Limitations

Organic growth in local currency




Americas

- Signs of a turnaround in Bracing & Support sales
- Organic growth 7%

EMEA

- Harvesting from major integration in 2006
- Strong organic growth of 12% in local currency
- Gibaud on track

Pro forma growth in local currency



Asia

- Sales flat

Prosthetics sales growth 11% in Local Currency

Bracing & Supports sales growth 30% in Local Currency

Compression therapy sales growth flat in Local Currency

PRODUCT INTRODUCTIONS Q3 2007



Life Without Limitations



Bracing & Support

- **Gameday™ Ankle Brace**
 - For ankle sprains and prophylactic use in sports

Prosthetics

- **Mauch® Knee Plus**
 - New version of the Mauch Knee
 - For users needing higher weight limits



*Few product introductions in Q3 and Q4 2007.
In the first half of 2008 some exciting upgrades
on braces are anticipated.*



Life Without Limitations

FINANCIALS – Q3 2007

HJORLEIFUR PALSSON – CFO

INCOME STATEMENTS Q3 2007




Life Without Limitations

Income Statements (USD '000)	Q3 2007	% of sales	Q3 2006	% of sales	Change
Net sales	82,322	100.0%	62,755	100.0%	31.2%
Cost of goods sold	(33,561)	-40.8%	(24,946)	-39.8%	34.5%
Gross profit	48,761	59.2%	37,809	60.2%	29.0%
Other income	311	0.4%	121	0.2%	157.0%
Sales & marketing expenses	(20,722)	-25.2%	(17,530)	-27.9%	18.2%
Research & development expenses	(5,324)	-6.5%	(4,254)	-6.8%	25.2%
General & administrative expenses	(14,901)	-18.1%	(9,085)	-14.5%	64.0%
Profit from operations	8,125	9.9%	7,061	11.3%	15.1%
Financial income /(expenses)	(5,840)	-7.1%	(3,887)	-6.2%	50.2%
Profit/(loss) before tax	2,285	2.8%	3,174	5.1%	-28.0%
Income tax	(130)	-0.2%	2,203	3.5%	-105.9%
Net profit for the period	2,155	2.6%	5,377	8.6%	-59.9%
EBITDA	14,068	17.1%	12,138	19.3%	15.9%

NET SALES BY QUARTER 2005 - 2007



Life Without Limitations




SALES BY BUSINESS SEGMENT Q3 2007




Life Without Limitations

Q3 2007



Q3 2006




USD '000	Q3 2007	Q3 2006	Growth in USD	Growth in LCY
Prosthetics	35,146	30,591	15%	11%
Bracing & Support	42,884	32,030	34%	30%
Compression therapy	3,074	0	n/a	n/a
Other	1,218	134	809%	713%
Total	82,322	62,755	31%	27%

SALES BY GEOGRAPHICAL MARKET Q3 2007




Life Without Limitations

Q3 2007



Q3 2006




USD '000	Q3 2007	Q3 2006	Growth in USD	Growth in LCY
Americas	42,419	36,669	7%	7%
EMEA	36,904	20,132	83%	71%
Asia	2,999	2,954	2%	0%
Total	82,322	62,755	31%	27%

EBITDA AND EBITDA RATIO 2004 - 2007




Life Without Limitations



NET CASH PROVIDED BY OPERATING ACTIVITIES



Life Without Limitations



BALANCE SHEETS 30 SEPTEMBER 2007



Life Without Limitations

USD '000	30 September 2007	31 December 2006	% Change
Fixed assets	491,751	489,319	0%
Current assets	133,317	123,433	8%
Total assets	625,068	612,752	2%
Stockholders' equity	171,089	161,639	6%
Long-term liabilities	233,661	234,538	0%
Current liabilities ¹⁾	220,318	216,575	2%
Total equity and liabilities	625,068	612,752	2%
Net Debt / EBITDA ²⁾	6.5-7.0x	8.9x	
Equity ratio	27%	26%	

1) A 100 million euro bridge loan facility agreement entered into in December 2006 to finance the acquisition of the Gibaud Group is included in current liabilities.

2) Estimated 2007 EBITDA.


CAPITAL INVESTMENTS Q3 2007




Life Without Limitations

Capital investments amounted to USD 1.1 million in Q3 2007, or 1.4% of sales

By location



By category



FINANCIAL HIGHLIGHTS YTD Q3 2007



Life Without Limitations

- Total sales USD 250.7 million, up 33% from 2006
- Organic sales growth 8%
- Pro forma sales growth 8%
- Profit from operations USD 23.6 million, up by 22%
- EBITDA 16.6% compared to 18% in 2006
- Net profit USD 0.9 million compared to USD 8.1 million in 2006
- Cash EPS diluted 4.94 US cents, down by 16%
- EPS diluted 0.24 US cents, down by 88%



INCOME STATEMENTS YTD Q3 2007



Life Without Limitations

Income Statement YTD Q3 2007 (USD '000)	YTD 2007	% of sales	YTD 2006	% of sales	% change
Net sales	250,739	100.0%	188,289	100.0%	33.2%
Cost of goods sold	(102,870)	-41.0%	(75,811)	-40.3%	35.7%
Gross profit	147,869	59.0%	112,478	59.7%	31.5%
Other income	828	0.3%	244	0.1%	239.3%
Sales & marketing expenses	(63,961)	-25.5%	(50,862)	-27.0%	25.8%
Research & development expenses	(14,917)	-5.9%	(13,181)	-7.0%	13.2%
General & administrative expenses	(46,260)	-18.4%	(26,380)	-14.0%	75.4%
Restructuring expenses			(3,000)	-1.6%	
Profit from operations	23,559	9.4%	19,299	10.2%	22.1%
Financial income /(expenses)	(23,218)	-9.3%	(14,795)	-7.9%	56.9%
Profit/(loss) before tax	341	0.1%	4,504	2.4%	-92.4%
Income tax	591	0.2%	3,563	1.9%	-83.4%
Net profit for the period	932	0.4%	8,067	4.3%	-88.4%
EBITDA	41,661	16.6%	33,877	18.0%	23.0%

MAIN SHAREHOLDERS 30 SEPTEMBER 2007



Life Without Limitations

		Nominal value	%	
1.	William Demant Invest A/S	Investment Fund	144,952,402	37.66
2.	Eyrir Invest ehf	Investment Company	84,040,215	21.83
3.	Mallard Holding S.A.	Founder & Family	37,526,769	9.75
4.	Vik Investment Holding S.a.r.L.	President & CEO	24,446,907	6.35
5.	Lífeyrissjóður verslunarmanna	Pension Fund	7,870,283	2.04
6.	Arion safnreikningur	Custody Bank	6,921,547	1.80
7.	Landsbanki Íslands hf	Bank	4,551,146	1.18
8.	BYR sparissjóður	Bank	4,443,231	1.15
9.	Mycenaean Holding S.a.r.L.	VP of R&D	3,560,347	0.92
10.	Sameinaði lífeyrissjóðurinn	Pension Fund	3,546,634	0.92
11.	Kaupping banki hf	Bank	3,142,264	0.82
12.	Gildi -lífeyrissjóður	Pension Fund	3,073,419	0.80
13.	Fidelity Funds	Investment Fund	2,356,100	0.61
14.	Ker Holding S.a.r.L.	President of Ossur Asia	2,124,450	0.55
15.	Cyclops Holding S.a.r.L.	President of Ossur Americas	2,027,900	0.53
Top 15 shareholders			334,583,614	86.91
Others			50,356,833	13.09
Total number of shares			384,940,447	100.00

